Panacea Biotec is currently trading at Rs 68.60, up by 0.50 points or 0.73% from its previous closing of Rs 68.10 on the BSE.
The scrip opened at Rs 68.95 and has touched a high and low of Rs 69.00 and Rs 67.50 respectively. So far 1320 shares were traded on the counter.
The BSE group 'B' stock of face value Re 1 has touched a 52 week high of Rs 199.45 on 26-Apr-2011 and a 52 week low of Rs 67.60 on 27-Mar-2012.
Last one week high and low of the scrip stood at Rs 70.85 and Rs 67.50 respectively. The current market cap of the company is Rs 416.51 crore.
The promoters holding in the company stood at 74.85% while Institutions and Non-Institutions held 3.18% and 21.97% respectively.
Panacea Biotec, India's leading vaccine manufacturer has inaugurated its new state-of-the-art Oncology facility at Baddi in Himachal Pradesh to meet the growing demand of anti-cancer products in the country.
The new manufacturing facility will entail an annual production of about 1.2 million vials, and being set up in compliance with various international regulatory standards like CGMP, USFDA and UK-MHRA. The plant has been set up with a project cost of about Rs 55 crore.
The company has been aggressively ramping up its production capacity, as well as introducing new business lines to cater to emerging business opportunities in various therapeutic segments. The company has released products for sales from commercial production from March 2012.
Panacea Biotec is one of India’s leading research based health management companies with established research, manufacturing and marketing capabilities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1837.15 |
| Dr. Reddys Lab | 1271.55 |
| Cipla | 1353.85 |
| Zydus Lifesciences | 1070.90 |
| Lupin | 2351.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: